Radiopharmaceutical Manufacturing Market Growth

Increasing investment to drive radiopharmaceutical manufacturing market growth; reaching $9 billion by 2035

 

According to a recently published report by Roots Analysis, the increasing prevalence of chronic diseases and growing demand for targeted radionuclide therapy is driving the radiopharmaceutical manufacturing market growth

Radiopharmaceutical Manufacturing Industry Overview

The global radiopharmaceutical manufacturing market size is anticipated to reach over USD 9 billion by 2035, growing at a CAGR of ~9% over the forecast period 2024-2035. 

Given the rising geriatric population along with increasing prevalence of chronic diseases, and surge in the number of imaging procedures using radiopharmaceuticals, the demand for novel radiolabeled drugs have grown significantly. Owing to their very short half-life, high target specificity and high affinity, radiopharmaceuticals have revolutionized the diagnosis and treatment of several chronic diseases (especially, cancer). However, it is important to note that the development and production of radiopharmaceuticals is fraught with several challenges, including shortage of production capacity, complex manufacturing process, lack of skilled labor and stringent regulatory guidelines mandated by regulatory agencies. This has prompted the drug developers to outsource certain key operations (specifically the complex manufacturing processes) to contract service providers, which further helps to reduce cost and expediate the launch of their radioactive drug products to the market.

Browse 125+ figures and 140+ market data tables spread across 340+ pages and detailed Table of Content on “Radiopharmaceutical Manufacturing Market by Application Area, Type of Diagnostic Radiopharmaceutical, Type of Therapeutic Radiopharmaceutical, Type of Radioisotope, Purpose of Manufacturing, Source of Manufacturing, Scale of Operation, Therapeutic Area and Key Geographical Regions: Industry Trends and Global Forecasts, till 2035” here: 
https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html

Market Drivers 

Several factors are propelling the growth of the radiopharmaceutical production market. Obesity, aging population and lifestyle habits have led to the rise in prevalence of chronic diseases in recent years, consequently leading to increase in demand for radiolabeled drugs that can effectively detect, target and / or destroy the diseased cells / organs. Further, the integration of artificial intelligence and machine learning is driving the advancements in the medical imaging domain. According to an article published by World Nuclear Association, more than 10,000 hospitals, worldwide, claim to use radioisotopes for various diagnostic and therapeutic purposes. Owing to the exponential rise in the patient population, the growing research and development activities and technological advancement, the nuclear medicine and radiopharmaceutical manufacturing market is expected to witness a significant rise in the foreseen future.

Market Restraints 

While the radiopharmaceutical manufacturing market is experiencing substantial growth, it is not without its challenges. One of the primary restraints is the high cost associated with the production of radiopharmaceuticals. Further, the establishment cost for cGMP facility and maintenance cost associated with the production facility is usually high. In addition, owing to the presence of radioactive isotopes, stringent regulatory compliance is of utmost importance for the manufacturers. Moreover, limited production capacity and transportation delays in the supply chain can also significantly disrupt the delivery of these critical short-lived radioactive drug substances to the potential end users.

Growth Factors

Despite the challenges, several growth factors continue to drive the nuclear medicine and radiopharmaceutical manufacturing market forward. One notable factor is the growing demand of novel radionuclide therapies. Over the past few years, researchers and developers have extensively focused on developing targeted therapies, thereby eliminating the limitations of conventional treatment options. It is worth highlighting that as of 2023, more than 200 clinical trials are currently underway to investigate various radiotherapeutics for the treatment of a myriad of chronic diseases. Further, the introduction of the concept of theranostics, which involves the usage of a single active ingredient for both diagnostic and therapeutic purposes, represents a promising paradigm in patient centric treatment approach.

Radiopharmaceutical Manufacturing Market Segments

Based on the Application Area, the market is segmented into Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals

• The diagnostic radiopharmaceutical segment led the radiopharmaceutical manufacturing market, capturing the largest revenue share in 2024.
• The therapeutic radiopharmaceutical segment is anticipated to show an annual growth rate of 17.4%, during the forecast period.

Based on the type of Diagnostic Radiopharmaceutical, the market is segmented into Positron Emission Tomography Radiopharmaceuticals and SPECT Radiopharmaceuticals

• The SPECT radiopharmaceuticals segment led the radiopharmaceutical manufacturing market, capturing the largest revenue share (78%) in 2024.
• The positron emission tomography radiopharmaceuticals segment is anticipated to show an annual growth rate of 4.4%, during the forecast period.

Based on the type of Therapeutic Radiopharmaceutical, the market is segmented into Alpha Emitters, Beta Emitters and Other Therapeutic Radiopharmaceuticals

• The beta emitters led the radiopharmaceutical manufacturing market, capturing the largest revenue share (65%) in 2024.
• The alpha emitters segment is anticipated to show an annual growth rate of 18.7%, during the forecast period.

Based on the Type of Radioisotope, the market is segmented into Technetium-99m, Fluorine-18, Leutetium-177, Gallium-68, Actinium-225 and Other Radioisotopes

• The Technetium-99m radioisotope segment led the radiopharmaceutical manufacturing market, capturing the largest revenue share of 40.0% in 2024.
• The Actinium-225 radioisotope segment is anticipated to show an annual growth rate of 11.2%, during the forecast period.

Based on the Purpose of Manufacturing, the market is segmented into Contract Manufacturing and In-House Manufacturing

• The in-house manufacturing of radiopharmaceuticals led the radiopharmaceutical manufacturing market, capturing the largest revenue share of over 70% in 2024.
• The contract manufacturing segment is anticipated to show an annual growth rate of 12%, during the forecast period.

Based on the Source of Manufacturing, the market is segmented into Nuclear Reactors and Cyclotrons

• The nuclear reactors segment led the radiopharmaceutical manufacturing market, capturing the largest revenue share of over 85% in 2024.
• The cyclotrons segment is anticipated to show an annual growth rate of 13.4%, during the forecast period.

Based on the Scale of Operation, the market is segmented into Preclinical, Clinical and Commercial

• The commercial scale segment led the radiopharmaceutical manufacturing market, capturing the largest revenue share of 85.0% in 2024.
• The preclinical scale segment is anticipated to show an annual growth rate of 9.8%, during the forecast period.

Based on the Therapeutic Area, the market is segmented into Cardiovascular Disorders, Neurological Disorders, Oncological Disorders and Other Disorders

• The oncological disorders segment led the radiopharmaceutical manufacturing market, capturing the largest revenue share of 40.0% in 2024.
• The neurological disorders segment is anticipated to show an annual growth rate of 11.6%, during the forecast period.

Based on the Regional Insights, the market is segmented into North America, Europe, Asia Pacific and Rest of the World

• North America dominated the radiopharmaceutical manufacturing market and accounted for the largest revenue share (50.0%) in 2024.
• In Asia Pacific, the radiopharmaceutical manufacturing market is anticipated to demonstrate lucrative growth during the forecast period.

Key Companies Profiled

The nuclear medicine and radiopharmaceutical manufacturing market report also includes profiles of key players (listed below) that engaged in the manufacturing of radiopharmaceuticals:
Advanced Accelerator Applications, Applied Molecular Therapies, Cardinal Health, DuChemBio, Eckert & Ziegler, Evergreen Theragnostics, Isotopia Molecular Imaging, ITM Isotope Technologies Munich, Nihon Medi-Physics, Nucleus RadioPharma, Pentixapharm, PharmaLogic, RadioMedix, SOFIE, Telix Pharmaceuticals

You Can Download Free Sample PDF Copy Of This Report At:
https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing/request-sample.html

About Roots Analysis

Roots Analysis is a specialist market research, competitive intelligence and consulting company, sharing fresh and independent perspectives for the industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com